Skip to main content
Top
Published in: Journal of Experimental & Clinical Cancer Research 1/2011

Open Access 01-12-2011 | Review

The mechanisms by which polyamines accelerate tumor spread

Author: Kuniyasu Soda

Published in: Journal of Experimental & Clinical Cancer Research | Issue 1/2011

Login to get access

Abstract

Increased polyamine concentrations in the blood and urine of cancer patients reflect the enhanced levels of polyamine synthesis in cancer tissues arising from increased activity of enzymes responsible for polyamine synthesis. In addition to their de novo polyamine synthesis, cells can take up polyamines from extracellular sources, such as cancer tissues, food, and intestinal microbiota. Because polyamines are indispensable for cell growth, increased polyamine availability enhances cell growth. However, the malignant potential of cancer is determined by its capability to invade to surrounding tissues and metastasize to distant organs. The mechanisms by which increased polyamine levels enhance the malignant potential of cancer cells and decrease anti-tumor immunity are reviewed. Cancer cells with a greater capability to synthesize polyamines are associated with increased production of proteinases, such as serine proteinase, matrix metalloproteinases, cathepsins, and plasminogen activator, which can degrade surrounding tissues. Although cancer tissues produce vascular growth factors, their deregulated growth induces hypoxia, which in turn enhances polyamine uptake by cancer cells to further augment cell migration and suppress CD44 expression. Increased polyamine uptake by immune cells also results in reduced cytokine production needed for anti-tumor activities and decreases expression of adhesion molecules involved in anti-tumor immunity, such as CD11a and CD56. Immune cells in an environment with increased polyamine levels lose anti-tumor immune functions, such as lymphokine activated killer activities. Recent investigations revealed that increased polyamine availability enhances the capability of cancer cells to invade and metastasize to new tissues while diminishing immune cells' anti-tumor immune functions.
Appendix
Available only for authorised users
Literature
1.
go back to reference Durie BG, Salmon SE, Russell DH: Polyamines as markers of response and disease activity in cancer chemotherapy. Cancer Res. 1977, 37: 214-221.PubMed Durie BG, Salmon SE, Russell DH: Polyamines as markers of response and disease activity in cancer chemotherapy. Cancer Res. 1977, 37: 214-221.PubMed
2.
go back to reference Loser C, Folsch UR, Paprotny C, Creutzfeldt W: Polyamines in colorectal cancer. Evaluation of polyamine concentrations in the colon tissue, serum, and urine of 50 patients with colorectal cancer. Cancer. 1990, 65: 958-966. 10.1002/1097-0142(19900215)65:4<958::AID-CNCR2820650423>3.0.CO;2-Z.PubMedCrossRef Loser C, Folsch UR, Paprotny C, Creutzfeldt W: Polyamines in colorectal cancer. Evaluation of polyamine concentrations in the colon tissue, serum, and urine of 50 patients with colorectal cancer. Cancer. 1990, 65: 958-966. 10.1002/1097-0142(19900215)65:4<958::AID-CNCR2820650423>3.0.CO;2-Z.PubMedCrossRef
3.
go back to reference Chatel M, Darcel F, Quemener V, Hercouet H, Moulinoux JP: Red blood cell polyamines as biochemical markers of supratentorial malignant gliomas. Anticancer Res. 1987, 7: 33-38.PubMed Chatel M, Darcel F, Quemener V, Hercouet H, Moulinoux JP: Red blood cell polyamines as biochemical markers of supratentorial malignant gliomas. Anticancer Res. 1987, 7: 33-38.PubMed
4.
go back to reference Kubota S, Okada M, Yoshimoto M, Murata N, Yamasaki Z, Wada T, Imahori K, Ohsawa N, Takaku F: Urinary polyamines as a tumor marker. Cancer Detect Prev. 1985, 8: 189-192.PubMed Kubota S, Okada M, Yoshimoto M, Murata N, Yamasaki Z, Wada T, Imahori K, Ohsawa N, Takaku F: Urinary polyamines as a tumor marker. Cancer Detect Prev. 1985, 8: 189-192.PubMed
5.
go back to reference Uehara N, Shirakawa S, Uchino H, Saeki Y: Elevated contents of spermidine and spermine in the erythrocytes of cancer patients. Cancer. 1980, 45: 108-111. 10.1002/1097-0142(19800101)45:1<108::AID-CNCR2820450120>3.0.CO;2-W.PubMedCrossRef Uehara N, Shirakawa S, Uchino H, Saeki Y: Elevated contents of spermidine and spermine in the erythrocytes of cancer patients. Cancer. 1980, 45: 108-111. 10.1002/1097-0142(19800101)45:1<108::AID-CNCR2820450120>3.0.CO;2-W.PubMedCrossRef
6.
go back to reference Cipolla B, Guille F, Moulinoux JP, Bansard JY, Roth S, Staerman F, Corbel L, Quemener V, Lobel B: Erythrocyte polyamines and prognosis in stage D2 prostatic carcinoma patients. J Urol. 1994, 151: 629-633.PubMed Cipolla B, Guille F, Moulinoux JP, Bansard JY, Roth S, Staerman F, Corbel L, Quemener V, Lobel B: Erythrocyte polyamines and prognosis in stage D2 prostatic carcinoma patients. J Urol. 1994, 151: 629-633.PubMed
7.
go back to reference Weiss TS, Bernhardt G, Buschauer A, Thasler WE, Dolgner D, Zirngibl H, Jauch KW: Polyamine levels of human colorectal adenocarcinomas are correlated with tumor stage and grade. Int J Colorectal Dis. 2002, 17: 381-387. 10.1007/s00384-002-0394-7.PubMedCrossRef Weiss TS, Bernhardt G, Buschauer A, Thasler WE, Dolgner D, Zirngibl H, Jauch KW: Polyamine levels of human colorectal adenocarcinomas are correlated with tumor stage and grade. Int J Colorectal Dis. 2002, 17: 381-387. 10.1007/s00384-002-0394-7.PubMedCrossRef
8.
go back to reference Linsalata M, Caruso MG, Leo S, Guerra V, D'Attoma B, Di Leo A: Prognostic value of tissue polyamine levels in human colorectal carcinoma. Anticancer Res. 2002, 22: 2465-2469.PubMed Linsalata M, Caruso MG, Leo S, Guerra V, D'Attoma B, Di Leo A: Prognostic value of tissue polyamine levels in human colorectal carcinoma. Anticancer Res. 2002, 22: 2465-2469.PubMed
9.
go back to reference Bergeron C, Bansard JY, Le Moine P, Bouet F, Goasguen JE, Moulinoux JP, Le Gall E, Catros-Quemener V: Erythrocyte spermine levels: a prognostic parameter in childhood common acute lymphoblastic leukemia. Leukemia. 1997, 11: 31-36. 10.1038/sj.leu.2400531.PubMedCrossRef Bergeron C, Bansard JY, Le Moine P, Bouet F, Goasguen JE, Moulinoux JP, Le Gall E, Catros-Quemener V: Erythrocyte spermine levels: a prognostic parameter in childhood common acute lymphoblastic leukemia. Leukemia. 1997, 11: 31-36. 10.1038/sj.leu.2400531.PubMedCrossRef
10.
11.
go back to reference Hochman J, Katz A, Bachrach U: Polyamines and protein kinase II. Effect of polyamines on cyclic AMP--dependent protein kinase from rat liver. Life Sci. 1978, 22: 1481-1484. 10.1016/0024-3205(78)90002-4.PubMedCrossRef Hochman J, Katz A, Bachrach U: Polyamines and protein kinase II. Effect of polyamines on cyclic AMP--dependent protein kinase from rat liver. Life Sci. 1978, 22: 1481-1484. 10.1016/0024-3205(78)90002-4.PubMedCrossRef
12.
go back to reference Tabib A, Bachrach U: Activation of the proto-oncogene c-myc and c-fos by c-ras: involvement of polyamines. Biochem Biophys Res Commun. 1994, 202: 720-727. 10.1006/bbrc.1994.1990.PubMedCrossRef Tabib A, Bachrach U: Activation of the proto-oncogene c-myc and c-fos by c-ras: involvement of polyamines. Biochem Biophys Res Commun. 1994, 202: 720-727. 10.1006/bbrc.1994.1990.PubMedCrossRef
13.
go back to reference Panagiotidis CA, Artandi S, Calame K, Silverstein SJ: Polyamines alter sequence-specific DNA-protein interactions. Nucleic Acids Res. 1995, 23: 1800-1809. 10.1093/nar/23.10.1800.PubMedCentralPubMedCrossRef Panagiotidis CA, Artandi S, Calame K, Silverstein SJ: Polyamines alter sequence-specific DNA-protein interactions. Nucleic Acids Res. 1995, 23: 1800-1809. 10.1093/nar/23.10.1800.PubMedCentralPubMedCrossRef
14.
go back to reference Childs AC, Mehta DJ, Gerner EW: Polyamine-dependent gene expression. Cell Mol Life Sci. 2003, 60: 1394-1406. 10.1007/s00018-003-2332-4.PubMedCrossRef Childs AC, Mehta DJ, Gerner EW: Polyamine-dependent gene expression. Cell Mol Life Sci. 2003, 60: 1394-1406. 10.1007/s00018-003-2332-4.PubMedCrossRef
15.
18.
go back to reference Gerner EW, Meyskens FL: Polyamines and cancer: old molecules, new understanding. Nat Rev Cancer. 2004, 4: 781-792. 10.1038/nrc1454.PubMedCrossRef Gerner EW, Meyskens FL: Polyamines and cancer: old molecules, new understanding. Nat Rev Cancer. 2004, 4: 781-792. 10.1038/nrc1454.PubMedCrossRef
19.
go back to reference Erdman SH, Ignatenko NA, Powell MB, Blohm-Mangone KA, Holubec H, Guillen-Rodriguez JM, Gerner EW: APC-dependent changes in expression of genes influencing polyamine metabolism, and consequences for gastrointestinal carcinogenesis, in the Min mouse. Carcinogenesis. 1999, 20: 1709-1713. 10.1093/carcin/20.9.1709.PubMedCrossRef Erdman SH, Ignatenko NA, Powell MB, Blohm-Mangone KA, Holubec H, Guillen-Rodriguez JM, Gerner EW: APC-dependent changes in expression of genes influencing polyamine metabolism, and consequences for gastrointestinal carcinogenesis, in the Min mouse. Carcinogenesis. 1999, 20: 1709-1713. 10.1093/carcin/20.9.1709.PubMedCrossRef
20.
go back to reference Becciolini A, Porciani S, Lanini A, Balzi M, Cionini L, Bandettini L: Polyamine levels in healthy and tumor tissues of patients with colon adenocarcinoma. Dis Colon Rectum. 1991, 34: 167-173. 10.1007/BF02049993.PubMedCrossRef Becciolini A, Porciani S, Lanini A, Balzi M, Cionini L, Bandettini L: Polyamine levels in healthy and tumor tissues of patients with colon adenocarcinoma. Dis Colon Rectum. 1991, 34: 167-173. 10.1007/BF02049993.PubMedCrossRef
21.
go back to reference Canizares F, Salinas J, de las Heras M, Diaz J, Tovar I, Martinez P, Penafiel R: Prognostic value of ornithine decarboxylase and polyamines in human breast cancer: correlation with clinicopathologic parameters. Clin Cancer Res. 1999, 5: 2035-2041.PubMed Canizares F, Salinas J, de las Heras M, Diaz J, Tovar I, Martinez P, Penafiel R: Prognostic value of ornithine decarboxylase and polyamines in human breast cancer: correlation with clinicopathologic parameters. Clin Cancer Res. 1999, 5: 2035-2041.PubMed
22.
go back to reference Radford DM, Nakai H, Eddy RL, Haley LL, Byers MG, Henry WM, Lawrence DD, Porter CW, Shows TB: Two chromosomal locations for human ornithine decarboxylase gene sequences and elevated expression in colorectal neoplasia. Cancer Res. 1990, 50: 6146-6153.PubMed Radford DM, Nakai H, Eddy RL, Haley LL, Byers MG, Henry WM, Lawrence DD, Porter CW, Shows TB: Two chromosomal locations for human ornithine decarboxylase gene sequences and elevated expression in colorectal neoplasia. Cancer Res. 1990, 50: 6146-6153.PubMed
23.
go back to reference Kingsnorth AN, Lumsden AB, Wallace HM: Polyamines in colorectal cancer. Br J Surg. 1984, 71: 791-794. 10.1002/bjs.1800711019.PubMedCrossRef Kingsnorth AN, Lumsden AB, Wallace HM: Polyamines in colorectal cancer. Br J Surg. 1984, 71: 791-794. 10.1002/bjs.1800711019.PubMedCrossRef
24.
go back to reference LaMuraglia GM, Lacaine F, Malt RA: High ornithine decarboxylase activity and polyamine levels in human colorectal neoplasia. Ann Surg. 1986, 204: 89-93. 10.1097/00000658-198607000-00013.PubMedCentralPubMedCrossRef LaMuraglia GM, Lacaine F, Malt RA: High ornithine decarboxylase activity and polyamine levels in human colorectal neoplasia. Ann Surg. 1986, 204: 89-93. 10.1097/00000658-198607000-00013.PubMedCentralPubMedCrossRef
25.
go back to reference Takenoshita S, Matsuzaki S, Nakano G, Kimura H, Hoshi H, Shoda H, Nakamura T: Selective elevation of the N1-acetylspermidine level in human colorectal adenocarcinomas. Cancer Res. 1984, 44: 845-847.PubMed Takenoshita S, Matsuzaki S, Nakano G, Kimura H, Hoshi H, Shoda H, Nakamura T: Selective elevation of the N1-acetylspermidine level in human colorectal adenocarcinomas. Cancer Res. 1984, 44: 845-847.PubMed
26.
go back to reference Moulinoux JP, Quemener V, Khan NA, Delcros JG, Havouis R: Spermidine uptake by erythrocytes from normal and Lewis lung carcinoma (3LL) grafted mice: I. In vitro study. Anticancer Res. 1989, 9: 1057-1062.PubMed Moulinoux JP, Quemener V, Khan NA, Delcros JG, Havouis R: Spermidine uptake by erythrocytes from normal and Lewis lung carcinoma (3LL) grafted mice: I. In vitro study. Anticancer Res. 1989, 9: 1057-1062.PubMed
27.
go back to reference Uda K, Tsujikawa T, Fujiyama Y, Bamba T: Rapid absorption of luminal polyamines in a rat small intestine ex vivo model. J Gastroenterol Hepatol. 2003, 18: 554-559. 10.1046/j.1440-1746.2003.03020.x.PubMedCrossRef Uda K, Tsujikawa T, Fujiyama Y, Bamba T: Rapid absorption of luminal polyamines in a rat small intestine ex vivo model. J Gastroenterol Hepatol. 2003, 18: 554-559. 10.1046/j.1440-1746.2003.03020.x.PubMedCrossRef
28.
go back to reference Bardocz S, Brown DS, Grant G, Pusztai A: Luminal and basolateral polyamine uptake by rat small intestine stimulated to grow by Phaseolus vulgaris lectin phytohaemagglutinin in vivo. Biochim Biophys Acta. 1990, 1034: 46-52.PubMedCrossRef Bardocz S, Brown DS, Grant G, Pusztai A: Luminal and basolateral polyamine uptake by rat small intestine stimulated to grow by Phaseolus vulgaris lectin phytohaemagglutinin in vivo. Biochim Biophys Acta. 1990, 1034: 46-52.PubMedCrossRef
29.
go back to reference Bardocz S, Grant G, Brown DS, Ralph A, Pusztai A: Polyamines in food--implications for growth and health. J Nutr Biochem. 1993, 4: 66-71. 10.1016/0955-2863(93)90001-D.CrossRef Bardocz S, Grant G, Brown DS, Ralph A, Pusztai A: Polyamines in food--implications for growth and health. J Nutr Biochem. 1993, 4: 66-71. 10.1016/0955-2863(93)90001-D.CrossRef
30.
go back to reference Soda K, Kano Y, Sakuragi M, Takao K, Lefor A, Konishi F: Long-term oral polyamine intake increases blood polyamine concentrations. J Nutr Sci Vitaminol (Tokyo). 2009, 55: 361-366. 10.3177/jnsv.55.361.CrossRef Soda K, Kano Y, Sakuragi M, Takao K, Lefor A, Konishi F: Long-term oral polyamine intake increases blood polyamine concentrations. J Nutr Sci Vitaminol (Tokyo). 2009, 55: 361-366. 10.3177/jnsv.55.361.CrossRef
31.
go back to reference Soda K, Dobashi Y, Kano Y, Tsujinaka S, Konishi F: Polyamine-rich food decreases age-associated pathology and mortality in aged mice. Exp Gerontol. 2009, 44: 727-732. 10.1016/j.exger.2009.08.013.PubMedCrossRef Soda K, Dobashi Y, Kano Y, Tsujinaka S, Konishi F: Polyamine-rich food decreases age-associated pathology and mortality in aged mice. Exp Gerontol. 2009, 44: 727-732. 10.1016/j.exger.2009.08.013.PubMedCrossRef
32.
go back to reference Brodal BP, Eliassen KA, Ronning H, Osmundsen H: Effects of dietary polyamines and clofibrate on metabolism of polyamines in the rat. J Nutr Biochem. 1999, 10: 700-708. 10.1016/S0955-2863(99)00058-3.PubMedCrossRef Brodal BP, Eliassen KA, Ronning H, Osmundsen H: Effects of dietary polyamines and clofibrate on metabolism of polyamines in the rat. J Nutr Biochem. 1999, 10: 700-708. 10.1016/S0955-2863(99)00058-3.PubMedCrossRef
33.
go back to reference Sarhan S, Knodgen B, Seiler N: The gastrointestinal tract as polyamine source for tumor growth. Anticancer Res. 1989, 9: 215-223.PubMed Sarhan S, Knodgen B, Seiler N: The gastrointestinal tract as polyamine source for tumor growth. Anticancer Res. 1989, 9: 215-223.PubMed
34.
go back to reference D'Agostino L, Pignata S, Daniele B, D'Adamo G, Ferraro C, Silvestro G, Tagliaferri P, Contegiacomo A, Gentile R, Tritto G, et al: Polyamine uptake by human colon carcinoma cell line CaCo-2. Digestion. 1990, 46 (Suppl 2): 352-359.PubMedCrossRef D'Agostino L, Pignata S, Daniele B, D'Adamo G, Ferraro C, Silvestro G, Tagliaferri P, Contegiacomo A, Gentile R, Tritto G, et al: Polyamine uptake by human colon carcinoma cell line CaCo-2. Digestion. 1990, 46 (Suppl 2): 352-359.PubMedCrossRef
35.
go back to reference Feige JJ, Chambaz EM: Polyamine uptake by bovine adrenocortical cells. Biochim Biophys Acta. 1985, 846: 93-100. 10.1016/0167-4889(85)90114-4.PubMedCrossRef Feige JJ, Chambaz EM: Polyamine uptake by bovine adrenocortical cells. Biochim Biophys Acta. 1985, 846: 93-100. 10.1016/0167-4889(85)90114-4.PubMedCrossRef
36.
go back to reference Cooper KD, Shukla JB, Rennert OM: Polyamine compartmentalization in various human disease states. Clin Chim Acta. 1978, 82: 1-7.PubMedCrossRef Cooper KD, Shukla JB, Rennert OM: Polyamine compartmentalization in various human disease states. Clin Chim Acta. 1978, 82: 1-7.PubMedCrossRef
37.
go back to reference Upp JR, Saydjari R, Townsend CM, Singh P, Barranco SC, Thompson JC: Polyamine levels and gastrin receptors in colon cancers. Ann Surg. 1988, 207: 662-669. 10.1097/00000658-198806000-00004.PubMedCentralPubMedCrossRef Upp JR, Saydjari R, Townsend CM, Singh P, Barranco SC, Thompson JC: Polyamine levels and gastrin receptors in colon cancers. Ann Surg. 1988, 207: 662-669. 10.1097/00000658-198806000-00004.PubMedCentralPubMedCrossRef
38.
go back to reference Hixson LJ, Garewal HS, McGee DL, Sloan D, Fennerty MB, Sampliner RE, Gerner EW: Ornithine decarboxylase and polyamines in colorectal neoplasia and mucosa. Cancer Epidemiol Biomarkers Prev. 1993, 2: 369-374.PubMed Hixson LJ, Garewal HS, McGee DL, Sloan D, Fennerty MB, Sampliner RE, Gerner EW: Ornithine decarboxylase and polyamines in colorectal neoplasia and mucosa. Cancer Epidemiol Biomarkers Prev. 1993, 2: 369-374.PubMed
39.
go back to reference Osborne DL, Seidel ER: Gastrointestinal luminal polyamines: cellular accumulation and enterohepatic circulation. Am J Physiol. 1990, 258: G576-584.PubMed Osborne DL, Seidel ER: Gastrointestinal luminal polyamines: cellular accumulation and enterohepatic circulation. Am J Physiol. 1990, 258: G576-584.PubMed
40.
go back to reference Kobayashi M, Xu YJ, Samejima K, Goda H, Niitsu M, Takahashi M, Hashimoto Y: Fate of orally administered 15N-labeled polyamines in rats bearing solid tumors. Biol Pharm Bull. 2003, 26: 285-288. 10.1248/bpb.26.285.PubMedCrossRef Kobayashi M, Xu YJ, Samejima K, Goda H, Niitsu M, Takahashi M, Hashimoto Y: Fate of orally administered 15N-labeled polyamines in rats bearing solid tumors. Biol Pharm Bull. 2003, 26: 285-288. 10.1248/bpb.26.285.PubMedCrossRef
41.
go back to reference Soda K, Kano Y, Nakamura T, Kasono K, Kawakami M, Konishi F: Spermine, a natural polyamine, suppresses LFA-1 expression on human lymphocyte. J Immunol. 2005, 175: 237-245.PubMedCrossRef Soda K, Kano Y, Nakamura T, Kasono K, Kawakami M, Konishi F: Spermine, a natural polyamine, suppresses LFA-1 expression on human lymphocyte. J Immunol. 2005, 175: 237-245.PubMedCrossRef
42.
go back to reference Kano Y, Soda K, Nakamura T, Saitoh M, Kawakami M, Konishi F: Increased blood spermine levels decrease the cytotoxic activity of lymphokine-activated killer cells: a novel mechanism of cancer evasion. Cancer Immunol Immunother. 2007, 56: 771-781. 10.1007/s00262-006-0229-4.PubMedCrossRef Kano Y, Soda K, Nakamura T, Saitoh M, Kawakami M, Konishi F: Increased blood spermine levels decrease the cytotoxic activity of lymphokine-activated killer cells: a novel mechanism of cancer evasion. Cancer Immunol Immunother. 2007, 56: 771-781. 10.1007/s00262-006-0229-4.PubMedCrossRef
43.
go back to reference Klein S, Miret JJ, Algranati ID, de Lustig ES: Effect of alpha-difluoromethylornithine in lung metastases before and after surgery of primary adenocarcinoma tumors in mice. Biol Cell. 1985, 53: 33-36.PubMedCrossRef Klein S, Miret JJ, Algranati ID, de Lustig ES: Effect of alpha-difluoromethylornithine in lung metastases before and after surgery of primary adenocarcinoma tumors in mice. Biol Cell. 1985, 53: 33-36.PubMedCrossRef
44.
go back to reference Herr HW, Kleinert EL, Conti PS, Burchenal JH, Whitmore WF: Effects of alpha-difluoromethylornithine and methylglyoxal bis(guanylhydrazone) on the growth of experimental renal adenocarcinoma in mice. Cancer Res. 1984, 44: 4382-4385.PubMed Herr HW, Kleinert EL, Conti PS, Burchenal JH, Whitmore WF: Effects of alpha-difluoromethylornithine and methylglyoxal bis(guanylhydrazone) on the growth of experimental renal adenocarcinoma in mice. Cancer Res. 1984, 44: 4382-4385.PubMed
45.
go back to reference Luk GD, Abeloff MD, Griffin CA, Baylin SB: Successful treatment with DL-alpha-difluoromethylornithine in established human small cell variant lung carcinoma implants in athymic mice. Cancer Res. 1983, 43: 4239-4243.PubMed Luk GD, Abeloff MD, Griffin CA, Baylin SB: Successful treatment with DL-alpha-difluoromethylornithine in established human small cell variant lung carcinoma implants in athymic mice. Cancer Res. 1983, 43: 4239-4243.PubMed
46.
go back to reference Kingsnorth AN, McCann PP, Diekema KA, Ross JS, Malt RA: Effects of alpha-difluoromethylornithine on the growth of experimental Wilms' tumor and renal adenocarcinoma. Cancer Res. 1983, 43: 4031-4034.PubMed Kingsnorth AN, McCann PP, Diekema KA, Ross JS, Malt RA: Effects of alpha-difluoromethylornithine on the growth of experimental Wilms' tumor and renal adenocarcinoma. Cancer Res. 1983, 43: 4031-4034.PubMed
47.
go back to reference Prados MD, Wara WM, Sneed PK, McDermott M, Chang SM, Rabbitt J, Page M, Malec M, Davis RL, Gutin PH, et al: Phase III trial of accelerated hyperfractionation with or without difluromethylornithine (DFMO) versus standard fractionated radiotherapy with or without DFMO for newly diagnosed patients with glioblastoma multiforme. Int J Radiat Oncol Biol Phys. 2001, 49: 71-77. 10.1016/S0360-3016(00)01458-9.PubMedCrossRef Prados MD, Wara WM, Sneed PK, McDermott M, Chang SM, Rabbitt J, Page M, Malec M, Davis RL, Gutin PH, et al: Phase III trial of accelerated hyperfractionation with or without difluromethylornithine (DFMO) versus standard fractionated radiotherapy with or without DFMO for newly diagnosed patients with glioblastoma multiforme. Int J Radiat Oncol Biol Phys. 2001, 49: 71-77. 10.1016/S0360-3016(00)01458-9.PubMedCrossRef
48.
go back to reference Messing E, Kim KM, Sharkey F, Schultz M, Parnes H, Kim D, Saltzstein D, Wilding G: Randomized prospective phase III trial of difluoromethylornithine vs placebo in preventing recurrence of completely resected low risk superficial bladder cancer. J Urol. 2006, 176: 500-504. 10.1016/j.juro.2006.03.061.PubMedCrossRef Messing E, Kim KM, Sharkey F, Schultz M, Parnes H, Kim D, Saltzstein D, Wilding G: Randomized prospective phase III trial of difluoromethylornithine vs placebo in preventing recurrence of completely resected low risk superficial bladder cancer. J Urol. 2006, 176: 500-504. 10.1016/j.juro.2006.03.061.PubMedCrossRef
49.
go back to reference Meyskens FL, McLaren CE, Pelot D, Fujikawa-Brooks S, Carpenter PM, Hawk E, Kelloff G, Lawson MJ, Kidao J, McCracken J, et al: Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial. Cancer Prev Res (Phila). 2008, 1: 32-38. 10.1158/1940-6207.CAPR-08-0042.CrossRef Meyskens FL, McLaren CE, Pelot D, Fujikawa-Brooks S, Carpenter PM, Hawk E, Kelloff G, Lawson MJ, Kidao J, McCracken J, et al: Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial. Cancer Prev Res (Phila). 2008, 1: 32-38. 10.1158/1940-6207.CAPR-08-0042.CrossRef
50.
go back to reference Quemener V, Moulinoux JP, Havouis R, Seiler N: Polyamine deprivation enhances antitumoral efficacy of chemotherapy. Anticancer Res. 1992, 12: 1447-1453.PubMed Quemener V, Moulinoux JP, Havouis R, Seiler N: Polyamine deprivation enhances antitumoral efficacy of chemotherapy. Anticancer Res. 1992, 12: 1447-1453.PubMed
51.
go back to reference Thompson PA, Wertheim BC, Zell JA, Chen WP, McLaren CE, LaFleur BJ, Meyskens FL, Gerner EW: Levels of rectal mucosal polyamines and prostaglandin E2 predict ability of DFMO and sulindac to prevent colorectal adenoma. Gastroenterology. 2010, 139: 797-805. 10.1053/j.gastro.2010.06.005. 805 e791PubMedCentralPubMedCrossRef Thompson PA, Wertheim BC, Zell JA, Chen WP, McLaren CE, LaFleur BJ, Meyskens FL, Gerner EW: Levels of rectal mucosal polyamines and prostaglandin E2 predict ability of DFMO and sulindac to prevent colorectal adenoma. Gastroenterology. 2010, 139: 797-805. 10.1053/j.gastro.2010.06.005. 805 e791PubMedCentralPubMedCrossRef
52.
go back to reference Levin VA, Hess KR, Choucair A, Flynn PJ, Jaeckle KA, Kyritsis AP, Yung WK, Prados MD, Bruner JM, Ictech S, et al: Phase III randomized study of postradiotherapy chemotherapy with combination alpha-difluoromethylornithine-PCV versus PCV for anaplastic gliomas. Clin Cancer Res. 2003, 9: 981-990.PubMed Levin VA, Hess KR, Choucair A, Flynn PJ, Jaeckle KA, Kyritsis AP, Yung WK, Prados MD, Bruner JM, Ictech S, et al: Phase III randomized study of postradiotherapy chemotherapy with combination alpha-difluoromethylornithine-PCV versus PCV for anaplastic gliomas. Clin Cancer Res. 2003, 9: 981-990.PubMed
53.
go back to reference Jun JY, Griffith JW, Bruggeman R, Washington S, Demers LM, Verderame MF, Manni A: Effects of polyamine depletion by alpha-difluoromethylornithine on in vitro and in vivo biological properties of 4T1 murine mammary cancer cells. Breast Cancer Res Treat. 2008, 107: 33-40.PubMedCrossRef Jun JY, Griffith JW, Bruggeman R, Washington S, Demers LM, Verderame MF, Manni A: Effects of polyamine depletion by alpha-difluoromethylornithine on in vitro and in vivo biological properties of 4T1 murine mammary cancer cells. Breast Cancer Res Treat. 2008, 107: 33-40.PubMedCrossRef
54.
go back to reference Kubota S, Ohsawa N, Takaku F: Effects of DL-alpha-difluoromethylornithine on the growth and metastasis of B16 melanoma in vivo. Int J Cancer. 1987, 39: 244-247. 10.1002/ijc.2910390220.PubMedCrossRef Kubota S, Ohsawa N, Takaku F: Effects of DL-alpha-difluoromethylornithine on the growth and metastasis of B16 melanoma in vivo. Int J Cancer. 1987, 39: 244-247. 10.1002/ijc.2910390220.PubMedCrossRef
55.
go back to reference Manni A, Washington S, Hu X, Griffith JW, Bruggeman R, Demers LM, Mauger D, Verderame MF: Effects of polyamine synthesis inhibitors on primary tumor features and metastatic capacity of human breast cancer cells. Clin Exp Metastasis. 2005, 22: 255-263. 10.1007/s10585-005-8480-1.PubMedCrossRef Manni A, Washington S, Hu X, Griffith JW, Bruggeman R, Demers LM, Mauger D, Verderame MF: Effects of polyamine synthesis inhibitors on primary tumor features and metastatic capacity of human breast cancer cells. Clin Exp Metastasis. 2005, 22: 255-263. 10.1007/s10585-005-8480-1.PubMedCrossRef
56.
go back to reference MacDonald NJ, Steeg PS: Molecular basis of tumour metastasis. Cancer Surv. 1993, 16: 175-199.PubMed MacDonald NJ, Steeg PS: Molecular basis of tumour metastasis. Cancer Surv. 1993, 16: 175-199.PubMed
57.
go back to reference Liotta LA, Rao CN, Barsky SH: Tumor invasion and the extracellular matrix. Lab Invest. 1983, 49: 636-649.PubMed Liotta LA, Rao CN, Barsky SH: Tumor invasion and the extracellular matrix. Lab Invest. 1983, 49: 636-649.PubMed
58.
go back to reference Klymkowsky MW, Savagner P: Epithelial-mesenchymal transition: a cancer researcher's conceptual friend and foe. Am J Pathol. 2009, 174: 1588-1593. 10.2353/ajpath.2009.080545.PubMedCentralPubMedCrossRef Klymkowsky MW, Savagner P: Epithelial-mesenchymal transition: a cancer researcher's conceptual friend and foe. Am J Pathol. 2009, 174: 1588-1593. 10.2353/ajpath.2009.080545.PubMedCentralPubMedCrossRef
59.
go back to reference Pouyssegur J, Dayan F, Mazure NM: Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature. 2006, 441: 437-443. 10.1038/nature04871.PubMedCrossRef Pouyssegur J, Dayan F, Mazure NM: Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature. 2006, 441: 437-443. 10.1038/nature04871.PubMedCrossRef
60.
go back to reference Hockel M, Vaupel P: Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst. 2001, 93: 266-276. 10.1093/jnci/93.4.266.PubMedCrossRef Hockel M, Vaupel P: Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst. 2001, 93: 266-276. 10.1093/jnci/93.4.266.PubMedCrossRef
61.
go back to reference Harris AL: Hypoxia--a key regulatory factor in tumour growth. Nat Rev Cancer. 2002, 2: 38-47. 10.1038/nrc704.PubMedCrossRef Harris AL: Hypoxia--a key regulatory factor in tumour growth. Nat Rev Cancer. 2002, 2: 38-47. 10.1038/nrc704.PubMedCrossRef
63.
go back to reference Hasan NM, Adams GE, Joiner MC, Marshall JF, Hart IR: Hypoxia facilitates tumour cell detachment by reducing expression of surface adhesion molecules and adhesion to extracellular matrices without loss of cell viability. Br J Cancer. 1998, 77: 1799-1805. 10.1038/bjc.1998.299.PubMedCentralPubMedCrossRef Hasan NM, Adams GE, Joiner MC, Marshall JF, Hart IR: Hypoxia facilitates tumour cell detachment by reducing expression of surface adhesion molecules and adhesion to extracellular matrices without loss of cell viability. Br J Cancer. 1998, 77: 1799-1805. 10.1038/bjc.1998.299.PubMedCentralPubMedCrossRef
64.
go back to reference Tantini B, Fiumana E, Cetrullo S, Pignatti C, Bonavita F, Shantz LM, Giordano E, Muscari C, Flamigni F, Guarnieri C, et al: Involvement of polyamines in apoptosis of cardiac myoblasts in a model of simulated ischemia. J Mol Cell Cardiol. 2006, 40: 775-782. 10.1016/j.yjmcc.2006.03.002.PubMedCrossRef Tantini B, Fiumana E, Cetrullo S, Pignatti C, Bonavita F, Shantz LM, Giordano E, Muscari C, Flamigni F, Guarnieri C, et al: Involvement of polyamines in apoptosis of cardiac myoblasts in a model of simulated ischemia. J Mol Cell Cardiol. 2006, 40: 775-782. 10.1016/j.yjmcc.2006.03.002.PubMedCrossRef
65.
go back to reference Aziz SM, Olson JW, Gillespie MN: Multiple polyamine transport pathways in cultured pulmonary artery smooth muscle cells: regulation by hypoxia. Am J Respir Cell Mol Biol. 1994, 10: 160-166.PubMedCrossRef Aziz SM, Olson JW, Gillespie MN: Multiple polyamine transport pathways in cultured pulmonary artery smooth muscle cells: regulation by hypoxia. Am J Respir Cell Mol Biol. 1994, 10: 160-166.PubMedCrossRef
66.
go back to reference Tsujinaka S, Soda K, Kano Y, Konishi F: Spermine accelerates hypoxia-initiated cancer cell migration. Int J Oncol. 2011, 38: 305-312.PubMed Tsujinaka S, Soda K, Kano Y, Konishi F: Spermine accelerates hypoxia-initiated cancer cell migration. Int J Oncol. 2011, 38: 305-312.PubMed
67.
go back to reference De Marzo AM, Bradshaw C, Sauvageot J, Epstein JI, Miller GJ: CD44 and CD44v6 downregulation in clinical prostatic carcinoma: relation to Gleason grade and cytoarchitecture. Prostate. 1998, 34: 162-168. 10.1002/(SICI)1097-0045(19980215)34:3<162::AID-PROS2>3.0.CO;2-K.PubMedCrossRef De Marzo AM, Bradshaw C, Sauvageot J, Epstein JI, Miller GJ: CD44 and CD44v6 downregulation in clinical prostatic carcinoma: relation to Gleason grade and cytoarchitecture. Prostate. 1998, 34: 162-168. 10.1002/(SICI)1097-0045(19980215)34:3<162::AID-PROS2>3.0.CO;2-K.PubMedCrossRef
68.
go back to reference Kallakury BV, Yang F, Figge J, Smith KE, Kausik SJ, Tacy NJ, Fisher HA, Kaufman R, Figge H, Ross JS: Decreased levels of CD44 protein and mRNA in prostate carcinoma. Correlation with tumor grade and ploidy. Cancer. 1996, 78: 1461-1469. 10.1002/(SICI)1097-0142(19961001)78:7<1461::AID-CNCR13>3.0.CO;2-Y.PubMedCrossRef Kallakury BV, Yang F, Figge J, Smith KE, Kausik SJ, Tacy NJ, Fisher HA, Kaufman R, Figge H, Ross JS: Decreased levels of CD44 protein and mRNA in prostate carcinoma. Correlation with tumor grade and ploidy. Cancer. 1996, 78: 1461-1469. 10.1002/(SICI)1097-0142(19961001)78:7<1461::AID-CNCR13>3.0.CO;2-Y.PubMedCrossRef
69.
go back to reference Sunkara PS, Rosenberger AL: Antimetastatic activity of DL-alpha-difluoromethylornithine, an inhibitor of polyamine biosynthesis, in mice. Cancer Res. 1987, 47: 933-935.PubMed Sunkara PS, Rosenberger AL: Antimetastatic activity of DL-alpha-difluoromethylornithine, an inhibitor of polyamine biosynthesis, in mice. Cancer Res. 1987, 47: 933-935.PubMed
70.
go back to reference Basset P, Okada A, Chenard MP, Kannan R, Stoll I, Anglard P, Bellocq JP, Rio MC: Matrix metalloproteinases as stromal effectors of human carcinoma progression: therapeutic implications. Matrix Biol. 1997, 15: 535-541. 10.1016/S0945-053X(97)90028-7.PubMedCrossRef Basset P, Okada A, Chenard MP, Kannan R, Stoll I, Anglard P, Bellocq JP, Rio MC: Matrix metalloproteinases as stromal effectors of human carcinoma progression: therapeutic implications. Matrix Biol. 1997, 15: 535-541. 10.1016/S0945-053X(97)90028-7.PubMedCrossRef
71.
go back to reference Nelson AR, Fingleton B, Rothenberg ML, Matrisian LM: Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol. 2000, 18: 1135-1149.PubMed Nelson AR, Fingleton B, Rothenberg ML, Matrisian LM: Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol. 2000, 18: 1135-1149.PubMed
72.
go back to reference Kessenbrock K, Plaks V, Werb Z: Matrix metalloproteinases: regulators of the tumor microenvironment. Cell. 2010, 141: 52-67. 10.1016/j.cell.2010.03.015.PubMedCentralPubMedCrossRef Kessenbrock K, Plaks V, Werb Z: Matrix metalloproteinases: regulators of the tumor microenvironment. Cell. 2010, 141: 52-67. 10.1016/j.cell.2010.03.015.PubMedCentralPubMedCrossRef
74.
go back to reference Kubota S, Kiyosawa H, Nomura Y, Yamada T, Seyama Y: Ornithine decarboxylase overexpression in mouse 10T1/2 fibroblasts: cellular transformation and invasion. J Natl Cancer Inst. 1997, 89: 567-571. 10.1093/jnci/89.8.567.PubMedCrossRef Kubota S, Kiyosawa H, Nomura Y, Yamada T, Seyama Y: Ornithine decarboxylase overexpression in mouse 10T1/2 fibroblasts: cellular transformation and invasion. J Natl Cancer Inst. 1997, 89: 567-571. 10.1093/jnci/89.8.567.PubMedCrossRef
75.
go back to reference Ashida Y, Kido J, Kinoshita F, Nishino M, Shinkai K, Akedo H, Inoue H: Putrescine-dependent invasive capacity of rat ascites hepatoma cells. Cancer Res. 1992, 52: 5313-5316.PubMed Ashida Y, Kido J, Kinoshita F, Nishino M, Shinkai K, Akedo H, Inoue H: Putrescine-dependent invasive capacity of rat ascites hepatoma cells. Cancer Res. 1992, 52: 5313-5316.PubMed
76.
go back to reference Wallon UM, Shassetz LR, Cress AE, Bowden GT, Gerner EW: Polyamine-dependent expression of the matrix metalloproteinase matrilysin in a human colon cancer-derived cell line. Mol Carcinog. 1994, 11: 138-144. 10.1002/mc.2940110304.PubMedCrossRef Wallon UM, Shassetz LR, Cress AE, Bowden GT, Gerner EW: Polyamine-dependent expression of the matrix metalloproteinase matrilysin in a human colon cancer-derived cell line. Mol Carcinog. 1994, 11: 138-144. 10.1002/mc.2940110304.PubMedCrossRef
77.
go back to reference Matters GL, Manni A, Bond JS: Inhibitors of polyamine biosynthesis decrease the expression of the metalloproteases meprin alpha and MMP-7 in hormone-independent human breast cancer cells. Clin Exp Metastasis. 2005, 22: 331-339. 10.1007/s10585-005-0660-5.PubMedCrossRef Matters GL, Manni A, Bond JS: Inhibitors of polyamine biosynthesis decrease the expression of the metalloproteases meprin alpha and MMP-7 in hormone-independent human breast cancer cells. Clin Exp Metastasis. 2005, 22: 331-339. 10.1007/s10585-005-0660-5.PubMedCrossRef
78.
go back to reference Auvinen M, Laine A, Paasinen-Sohns A, Kangas A, Kangas L, Saksela O, Andersson LC, Holtta E: Human ornithine decarboxylase-overproducing NIH3T3 cells induce rapidly growing, highly vascularized tumors in nude mice. Cancer Res. 1997, 57: 3016-3025.PubMed Auvinen M, Laine A, Paasinen-Sohns A, Kangas A, Kangas L, Saksela O, Andersson LC, Holtta E: Human ornithine decarboxylase-overproducing NIH3T3 cells induce rapidly growing, highly vascularized tumors in nude mice. Cancer Res. 1997, 57: 3016-3025.PubMed
79.
go back to reference Takigawa M, Enomoto M, Nishida Y, Pan HO, Kinoshita A, Suzuki F: Tumor angiogenesis and polyamines: alpha-difluoromethylornithine, an irreversible inhibitor of ornithine decarboxylase, inhibits B16 melanoma-induced angiogenesis in ovo and the proliferation of vascular endothelial cells in vitro. Cancer Res. 1990, 50: 4131-4138.PubMed Takigawa M, Enomoto M, Nishida Y, Pan HO, Kinoshita A, Suzuki F: Tumor angiogenesis and polyamines: alpha-difluoromethylornithine, an irreversible inhibitor of ornithine decarboxylase, inhibits B16 melanoma-induced angiogenesis in ovo and the proliferation of vascular endothelial cells in vitro. Cancer Res. 1990, 50: 4131-4138.PubMed
80.
go back to reference Hersh EM, Gschwind C, Morris DL, Murphy S: Deficient strongly adherent monocytes in the peripheral blood of cancer patients. Cancer Immunol Immunother. 1982, 14: 105-109.PubMed Hersh EM, Gschwind C, Morris DL, Murphy S: Deficient strongly adherent monocytes in the peripheral blood of cancer patients. Cancer Immunol Immunother. 1982, 14: 105-109.PubMed
81.
go back to reference Grosser N, Marti JH, Proctor JW, Thomson DM: Tube leukocyte adherence inhibition assay for the detection of anti-tumor immunity. I. Monocyte is the reactive cell. Int J Cancer. 1976, 18: 39-47. 10.1002/ijc.2910180107.PubMedCrossRef Grosser N, Marti JH, Proctor JW, Thomson DM: Tube leukocyte adherence inhibition assay for the detection of anti-tumor immunity. I. Monocyte is the reactive cell. Int J Cancer. 1976, 18: 39-47. 10.1002/ijc.2910180107.PubMedCrossRef
82.
go back to reference MacFarlane JK, Thomson DM, Phelan K, Shenouda G, Scanzano R: Predictive value of tube leukocyte adherence inhibition (LAI) assay for breast, colorectal, stomach and pancreatic cancer. Cancer. 1982, 49: 1185-1193. 10.1002/1097-0142(19820315)49:6<1185::AID-CNCR2820490620>3.0.CO;2-E.PubMedCrossRef MacFarlane JK, Thomson DM, Phelan K, Shenouda G, Scanzano R: Predictive value of tube leukocyte adherence inhibition (LAI) assay for breast, colorectal, stomach and pancreatic cancer. Cancer. 1982, 49: 1185-1193. 10.1002/1097-0142(19820315)49:6<1185::AID-CNCR2820490620>3.0.CO;2-E.PubMedCrossRef
83.
go back to reference Heriot AG, Marriott JB, Cookson S, Kumar D, Dalgleish AG: Reduction in cytokine production in colorectal cancer patients: association with stage and reversal by resection. Br J Cancer. 2000, 82: 1009-1012. 10.1054/bjoc.1999.1034.PubMedCentralPubMedCrossRef Heriot AG, Marriott JB, Cookson S, Kumar D, Dalgleish AG: Reduction in cytokine production in colorectal cancer patients: association with stage and reversal by resection. Br J Cancer. 2000, 82: 1009-1012. 10.1054/bjoc.1999.1034.PubMedCentralPubMedCrossRef
84.
go back to reference Rampone B, Rampone A, Tirabasso S, Panariello S, Rampone N: Immunological variations in women suffering from ovarian cancer. Influence of radical surgical treatment. Minerva Ginecol. 2001, 53: 116-119.PubMed Rampone B, Rampone A, Tirabasso S, Panariello S, Rampone N: Immunological variations in women suffering from ovarian cancer. Influence of radical surgical treatment. Minerva Ginecol. 2001, 53: 116-119.PubMed
85.
go back to reference Monson JR, Ramsden C, Guillou PJ: Decreased interleukin-2 production in patients with gastrointestinal cancer. Br J Surg. 1986, 73: 483-486. 10.1002/bjs.1800730620.PubMedCrossRef Monson JR, Ramsden C, Guillou PJ: Decreased interleukin-2 production in patients with gastrointestinal cancer. Br J Surg. 1986, 73: 483-486. 10.1002/bjs.1800730620.PubMedCrossRef
86.
go back to reference Wood NL, Kitces EN, Blaylock WK: Depressed lymphokine activated killer cell activity in mycosis fungoides. A possible marker for aggressive disease. Arch Dermatol. 1990, 126: 907-913. 10.1001/archderm.126.7.907.PubMedCrossRef Wood NL, Kitces EN, Blaylock WK: Depressed lymphokine activated killer cell activity in mycosis fungoides. A possible marker for aggressive disease. Arch Dermatol. 1990, 126: 907-913. 10.1001/archderm.126.7.907.PubMedCrossRef
87.
go back to reference Hermann GG, Petersen KR, Steven K, Zeuthen J: Reduced LAK cytotoxicity of peripheral blood mononuclear cells in patients with bladder cancer: decreased LAK cytotoxicity caused by a low incidence of CD56+ and CD57+ mononuclear blood cells. J Clin Immunol. 1990, 10: 311-320. 10.1007/BF00917476.PubMedCrossRef Hermann GG, Petersen KR, Steven K, Zeuthen J: Reduced LAK cytotoxicity of peripheral blood mononuclear cells in patients with bladder cancer: decreased LAK cytotoxicity caused by a low incidence of CD56+ and CD57+ mononuclear blood cells. J Clin Immunol. 1990, 10: 311-320. 10.1007/BF00917476.PubMedCrossRef
88.
go back to reference Funk J, Schmitz G, Failing K, Burkhardt E: Natural killer (NK) and lymphokine-activated killer (LAK) cell functions from healthy dogs and 29 dogs with a variety of spontaneous neoplasms. Cancer Immunol Immunother. 2005, 54: 87-92. 10.1007/s00262-004-0555-3.PubMedCrossRef Funk J, Schmitz G, Failing K, Burkhardt E: Natural killer (NK) and lymphokine-activated killer (LAK) cell functions from healthy dogs and 29 dogs with a variety of spontaneous neoplasms. Cancer Immunol Immunother. 2005, 54: 87-92. 10.1007/s00262-004-0555-3.PubMedCrossRef
89.
go back to reference Balch CM, Itoh K, Tilden AB: Cellular immune defects in patients with melanoma involving interleukin-2-activated lymphocyte cytotoxicity and a serum suppressor factor. Surgery. 1985, 98: 151-157.PubMed Balch CM, Itoh K, Tilden AB: Cellular immune defects in patients with melanoma involving interleukin-2-activated lymphocyte cytotoxicity and a serum suppressor factor. Surgery. 1985, 98: 151-157.PubMed
90.
go back to reference Hersey P, Bindon C, Czerniecki M, Spurling A, Wass J, McCarthy WH: Inhibition of interleukin 2 production by factors released from tumor cells. J Immunol. 1983, 131: 2837-2842.PubMed Hersey P, Bindon C, Czerniecki M, Spurling A, Wass J, McCarthy WH: Inhibition of interleukin 2 production by factors released from tumor cells. J Immunol. 1983, 131: 2837-2842.PubMed
91.
go back to reference Taylor DD, Bender DP, Gercel-Taylor C, Stanson J, Whiteside TL: Modulation of TcR/CD3-zeta chain expression by a circulating factor derived from ovarian cancer patients. Br J Cancer. 2001, 84: 1624-1629. 10.1054/bjoc.2001.1847.PubMedCentralPubMedCrossRef Taylor DD, Bender DP, Gercel-Taylor C, Stanson J, Whiteside TL: Modulation of TcR/CD3-zeta chain expression by a circulating factor derived from ovarian cancer patients. Br J Cancer. 2001, 84: 1624-1629. 10.1054/bjoc.2001.1847.PubMedCentralPubMedCrossRef
92.
go back to reference Byrd WJ, Jacobs DM, Amoss MS: Synthetic polyamines added to cultures containing bovine sera reversibly inhibit in vitro parameters of immunity. Nature. 1977, 267: 621-623. 10.1038/267621a0.PubMedCrossRef Byrd WJ, Jacobs DM, Amoss MS: Synthetic polyamines added to cultures containing bovine sera reversibly inhibit in vitro parameters of immunity. Nature. 1977, 267: 621-623. 10.1038/267621a0.PubMedCrossRef
93.
go back to reference Chamaillard L, Catros-Quemener V, Delcros JG, Bansard JY, Havouis R, Desury D, Commeurec A, Genetet N, Moulinoux JP: Polyamine deprivation prevents the development of tumour-induced immune suppression. Br J Cancer. 1997, 76: 365-370. 10.1038/bjc.1997.391.PubMedCentralPubMedCrossRef Chamaillard L, Catros-Quemener V, Delcros JG, Bansard JY, Havouis R, Desury D, Commeurec A, Genetet N, Moulinoux JP: Polyamine deprivation prevents the development of tumour-induced immune suppression. Br J Cancer. 1997, 76: 365-370. 10.1038/bjc.1997.391.PubMedCentralPubMedCrossRef
94.
go back to reference Lotzova E, Savary CA, Totpal K, Schachner J, Lichtiger B, McCredie KB, Freireich EJ: Highly oncolytic adherent lymphocytes: therapeutic relevance for leukemia. Leuk Res. 1991, 15: 245-254. 10.1016/0145-2126(91)90127-F.PubMedCrossRef Lotzova E, Savary CA, Totpal K, Schachner J, Lichtiger B, McCredie KB, Freireich EJ: Highly oncolytic adherent lymphocytes: therapeutic relevance for leukemia. Leuk Res. 1991, 15: 245-254. 10.1016/0145-2126(91)90127-F.PubMedCrossRef
95.
go back to reference Loser C, Folsch UR, Paprotny C, Creutzfeldt W: Polyamine concentrations in pancreatic tissue, serum, and urine of patients with pancreatic cancer. Pancreas. 1990, 5: 119-127. 10.1097/00006676-199003000-00001.PubMedCrossRef Loser C, Folsch UR, Paprotny C, Creutzfeldt W: Polyamine concentrations in pancreatic tissue, serum, and urine of patients with pancreatic cancer. Pancreas. 1990, 5: 119-127. 10.1097/00006676-199003000-00001.PubMedCrossRef
96.
go back to reference Nishiguchi S, Tamori A, Koh N, Fujimoto S, Takeda T, Shiomi S, Oka H, Yano Y, Otani S, Kuroki T: Erythrocyte-binding polyamine as a tumor growth marker for human hepatocellular carcinoma. Hepatogastroenterology. 2002, 49: 504-507.PubMed Nishiguchi S, Tamori A, Koh N, Fujimoto S, Takeda T, Shiomi S, Oka H, Yano Y, Otani S, Kuroki T: Erythrocyte-binding polyamine as a tumor growth marker for human hepatocellular carcinoma. Hepatogastroenterology. 2002, 49: 504-507.PubMed
97.
go back to reference Nishioka K, Romsdahl MM, McMurtrey MJ: Serum polyamine alterations in surgical patients with colorectal carcinoma. J Surg Oncol. 1977, 9: 555-562. 10.1002/jso.2930090605.PubMedCrossRef Nishioka K, Romsdahl MM, McMurtrey MJ: Serum polyamine alterations in surgical patients with colorectal carcinoma. J Surg Oncol. 1977, 9: 555-562. 10.1002/jso.2930090605.PubMedCrossRef
98.
go back to reference Colombatto S, Fasulo L, Fulgosi B, Grillo MA: Transport and metabolism of polyamines in human lymphocytes. Int J Biochem. 1990, 22: 489-492. 10.1016/0020-711X(90)90262-2.PubMedCrossRef Colombatto S, Fasulo L, Fulgosi B, Grillo MA: Transport and metabolism of polyamines in human lymphocytes. Int J Biochem. 1990, 22: 489-492. 10.1016/0020-711X(90)90262-2.PubMedCrossRef
99.
go back to reference Bardocz S, Grant G, Brown DS, Ewen SW, Nevison I, Pusztai A: Polyamine metabolism and uptake during Phaseolus vulgaris lectin, PHA-induced growth of rat small intestine. Digestion. 1990, 46 (Suppl 2): 360-366.PubMed Bardocz S, Grant G, Brown DS, Ewen SW, Nevison I, Pusztai A: Polyamine metabolism and uptake during Phaseolus vulgaris lectin, PHA-induced growth of rat small intestine. Digestion. 1990, 46 (Suppl 2): 360-366.PubMed
100.
go back to reference Cohen LF, Lundgren DW, Farrell PM: Distribution of spermidine and spermine in blood from cystic fibrosis patients and control subjects. Blood. 1976, 48: 469-475.PubMed Cohen LF, Lundgren DW, Farrell PM: Distribution of spermidine and spermine in blood from cystic fibrosis patients and control subjects. Blood. 1976, 48: 469-475.PubMed
101.
go back to reference Ellis TM, Fisher RI: Functional heterogeneity of Leu 19"bright"+ and Leu 19"dim"+ lymphokine-activated killer cells. J Immunol. 1989, 142: 2949-2954.PubMed Ellis TM, Fisher RI: Functional heterogeneity of Leu 19"bright"+ and Leu 19"dim"+ lymphokine-activated killer cells. J Immunol. 1989, 142: 2949-2954.PubMed
102.
go back to reference Weil-Hillman G, Fisch P, Prieve AF, Sosman JA, Hank JA, Sondel PM: Lymphokine-activated killer activity induced by in vivo interleukin 2 therapy: predominant role for lymphocytes with increased expression of CD2 and leu19 antigens but negative expression of CD16 antigens. Cancer Res. 1989, 49: 3680-3688.PubMed Weil-Hillman G, Fisch P, Prieve AF, Sosman JA, Hank JA, Sondel PM: Lymphokine-activated killer activity induced by in vivo interleukin 2 therapy: predominant role for lymphocytes with increased expression of CD2 and leu19 antigens but negative expression of CD16 antigens. Cancer Res. 1989, 49: 3680-3688.PubMed
103.
go back to reference Mule JJ, Shu S, Schwarz SL, Rosenberg SA: Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2. Science. 1984, 225: 1487-1489. 10.1126/science.6332379.PubMedCrossRef Mule JJ, Shu S, Schwarz SL, Rosenberg SA: Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2. Science. 1984, 225: 1487-1489. 10.1126/science.6332379.PubMedCrossRef
104.
go back to reference Rosenberg SA, Mule JJ, Spiess PJ, Reichert CM, Schwarz SL: Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2. J Exp Med. 1985, 161: 1169-1188. 10.1084/jem.161.5.1169.PubMedCrossRef Rosenberg SA, Mule JJ, Spiess PJ, Reichert CM, Schwarz SL: Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2. J Exp Med. 1985, 161: 1169-1188. 10.1084/jem.161.5.1169.PubMedCrossRef
105.
go back to reference Soda K, Kano Y, Nakamura T, Kawakami M, Konishi F: Spermine and spermidine induce some of the immune suppression observed in cancer patients. Annals of Cancer Research and Therapy. 2003, 11: 243-253.CrossRef Soda K, Kano Y, Nakamura T, Kawakami M, Konishi F: Spermine and spermidine induce some of the immune suppression observed in cancer patients. Annals of Cancer Research and Therapy. 2003, 11: 243-253.CrossRef
106.
go back to reference Zhang M, Caragine T, Wang H, Cohen PS, Botchkina G, Soda K, Bianchi M, Ulrich P, Cerami A, Sherry B, Tracey KJ: Spermine inhibits proinflammatory cytokine synthesis in human mononuclear cells: a counterregulatory mechanism that restrains the immune response. J Exp Med. 1997, 185: 1759-1768. 10.1084/jem.185.10.1759.PubMedCentralPubMedCrossRef Zhang M, Caragine T, Wang H, Cohen PS, Botchkina G, Soda K, Bianchi M, Ulrich P, Cerami A, Sherry B, Tracey KJ: Spermine inhibits proinflammatory cytokine synthesis in human mononuclear cells: a counterregulatory mechanism that restrains the immune response. J Exp Med. 1997, 185: 1759-1768. 10.1084/jem.185.10.1759.PubMedCentralPubMedCrossRef
107.
go back to reference Hasko G, Kuhel DG, Marton A, Nemeth ZH, Deitch EA, Szabo C: Spermine differentially regulates the production of interleukin-12 p40 and interleukin-10 and suppresses the release of the T helper 1 cytokine interferon-gamma. Shock. 2000, 14: 144-149. 10.1097/00024382-200014020-00012.PubMedCrossRef Hasko G, Kuhel DG, Marton A, Nemeth ZH, Deitch EA, Szabo C: Spermine differentially regulates the production of interleukin-12 p40 and interleukin-10 and suppresses the release of the T helper 1 cytokine interferon-gamma. Shock. 2000, 14: 144-149. 10.1097/00024382-200014020-00012.PubMedCrossRef
108.
go back to reference Bowlin TL, McKown BJ, Sunkara PS: The effect of alpha-difluoromethylornithine, an inhibitor of polyamine biosynthesis, on mitogen-induced interleukin 2 production. Immunopharmacology. 1987, 13: 143-147. 10.1016/0162-3109(87)90051-8.PubMedCrossRef Bowlin TL, McKown BJ, Sunkara PS: The effect of alpha-difluoromethylornithine, an inhibitor of polyamine biosynthesis, on mitogen-induced interleukin 2 production. Immunopharmacology. 1987, 13: 143-147. 10.1016/0162-3109(87)90051-8.PubMedCrossRef
109.
go back to reference Chamaillard L, Quemener V, Havouis R, Moulinoux JP: Polyamine deprivation stimulates natural killer cell activity in cancerous mice. Anticancer Res. 1993, 13: 1027-1033.PubMed Chamaillard L, Quemener V, Havouis R, Moulinoux JP: Polyamine deprivation stimulates natural killer cell activity in cancerous mice. Anticancer Res. 1993, 13: 1027-1033.PubMed
110.
go back to reference Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B: An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA. 1975, 72: 3666-3670. 10.1073/pnas.72.9.3666.PubMedCentralPubMedCrossRef Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B: An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA. 1975, 72: 3666-3670. 10.1073/pnas.72.9.3666.PubMedCentralPubMedCrossRef
111.
go back to reference Wacholtz MC, Patel SS, Lipsky PE: Leukocyte function-associated antigen 1 is an activation molecule for human T cells. J Exp Med. 1989, 170: 431-448. 10.1084/jem.170.2.431.PubMedCrossRef Wacholtz MC, Patel SS, Lipsky PE: Leukocyte function-associated antigen 1 is an activation molecule for human T cells. J Exp Med. 1989, 170: 431-448. 10.1084/jem.170.2.431.PubMedCrossRef
112.
go back to reference Ferrini S, Sforzini S, Cambiaggi A, Poggi A, Meazza R, Canevari S, Colnaghi MI, Moretta L: The LFA-1/ICAM cell adhesion pathway is involved in tumor-cell lysis mediated by bispecific monoclonal-antibody-targeted T lymphocytes. Int J Cancer. 1994, 56: 846-852. 10.1002/ijc.2910560616.PubMedCrossRef Ferrini S, Sforzini S, Cambiaggi A, Poggi A, Meazza R, Canevari S, Colnaghi MI, Moretta L: The LFA-1/ICAM cell adhesion pathway is involved in tumor-cell lysis mediated by bispecific monoclonal-antibody-targeted T lymphocytes. Int J Cancer. 1994, 56: 846-852. 10.1002/ijc.2910560616.PubMedCrossRef
113.
go back to reference Sarhan S, Weibel M, Seiler N: Effect of polyamine deprivation on the survival of intracranial glioblastoma bearing rats. Anticancer Res. 1991, 11: 987-992.PubMed Sarhan S, Weibel M, Seiler N: Effect of polyamine deprivation on the survival of intracranial glioblastoma bearing rats. Anticancer Res. 1991, 11: 987-992.PubMed
114.
go back to reference Seiler N, Sarhan S, Grauffel C, Jones R, Knodgen B, Moulinoux JP: Endogenous and exogenous polyamines in support of tumor growth. Cancer Res. 1990, 50: 5077-5083.PubMed Seiler N, Sarhan S, Grauffel C, Jones R, Knodgen B, Moulinoux JP: Endogenous and exogenous polyamines in support of tumor growth. Cancer Res. 1990, 50: 5077-5083.PubMed
115.
go back to reference Cipolla BG, Havouis R, Moulinoux JP: Polyamine reduced diet (PRD) nutrition therapy in hormone refractory prostate cancer patients. Biomed Pharmacother. 2010, 64: 363-368. 10.1016/j.biopha.2009.09.022.PubMedCrossRef Cipolla BG, Havouis R, Moulinoux JP: Polyamine reduced diet (PRD) nutrition therapy in hormone refractory prostate cancer patients. Biomed Pharmacother. 2010, 64: 363-368. 10.1016/j.biopha.2009.09.022.PubMedCrossRef
116.
go back to reference Page GG, Ben-Eliyahu S, Liebeskind JC: The role of LGL/NK cells in surgery-induced promotion of metastasis and its attenuation by morphine. Brain Behav Immun. 1994, 8: 241-250. 10.1006/brbi.1994.1022.PubMedCrossRef Page GG, Ben-Eliyahu S, Liebeskind JC: The role of LGL/NK cells in surgery-induced promotion of metastasis and its attenuation by morphine. Brain Behav Immun. 1994, 8: 241-250. 10.1006/brbi.1994.1022.PubMedCrossRef
117.
go back to reference Pollock RE, Babcock GF, Romsdahl MM, Nishioka K: Surgical stress-mediated suppression of murine natural killer cell cytotoxicity. Cancer Res. 1984, 44: 3888-3891.PubMed Pollock RE, Babcock GF, Romsdahl MM, Nishioka K: Surgical stress-mediated suppression of murine natural killer cell cytotoxicity. Cancer Res. 1984, 44: 3888-3891.PubMed
118.
go back to reference Hattori T, Hamai Y, Harada T, Ikeda H, Ikeda T: Enhancing effect of thoracotomy and/or laparotomy on the development of the lung metastases in rats after intravenous inoculation of tumor cells. Jpn J Surg. 1977, 7: 263-268. 10.1007/BF02469360.PubMedCrossRef Hattori T, Hamai Y, Harada T, Ikeda H, Ikeda T: Enhancing effect of thoracotomy and/or laparotomy on the development of the lung metastases in rats after intravenous inoculation of tumor cells. Jpn J Surg. 1977, 7: 263-268. 10.1007/BF02469360.PubMedCrossRef
119.
go back to reference Tsukamoto T, Kinoshita H, Hirohashi K, Kubo S, Otani S: Human erythrocyte polyamine levels after partial hepatectomy. Hepatogastroenterology. 1997, 44: 744-750.PubMed Tsukamoto T, Kinoshita H, Hirohashi K, Kubo S, Otani S: Human erythrocyte polyamine levels after partial hepatectomy. Hepatogastroenterology. 1997, 44: 744-750.PubMed
120.
go back to reference Aziz SM, Gillespie MN, Crooks PA, Tofiq SF, Tsuboi CP, Olson JW, Gosland MP: The potential of a novel polyamine transport inhibitor in cancer chemotherapy. J Pharmacol Exp Ther. 1996, 278: 185-192.PubMed Aziz SM, Gillespie MN, Crooks PA, Tofiq SF, Tsuboi CP, Olson JW, Gosland MP: The potential of a novel polyamine transport inhibitor in cancer chemotherapy. J Pharmacol Exp Ther. 1996, 278: 185-192.PubMed
121.
go back to reference Chen Y, Weeks RS, Burns MR, Boorman DW, Klein-Szanto A, O'Brien TG: Combination therapy with 2-difluoromethylornithine and a polyamine transport inhibitor against murine squamous cell carcinoma. Int J Cancer. 2006, 118: 2344-2349. 10.1002/ijc.21621.PubMedCrossRef Chen Y, Weeks RS, Burns MR, Boorman DW, Klein-Szanto A, O'Brien TG: Combination therapy with 2-difluoromethylornithine and a polyamine transport inhibitor against murine squamous cell carcinoma. Int J Cancer. 2006, 118: 2344-2349. 10.1002/ijc.21621.PubMedCrossRef
Metadata
Title
The mechanisms by which polyamines accelerate tumor spread
Author
Kuniyasu Soda
Publication date
01-12-2011
Publisher
BioMed Central
Published in
Journal of Experimental & Clinical Cancer Research / Issue 1/2011
Electronic ISSN: 1756-9966
DOI
https://doi.org/10.1186/1756-9966-30-95

Other articles of this Issue 1/2011

Journal of Experimental & Clinical Cancer Research 1/2011 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine